MaaT Pharma Reports Positive Phase 3 Results for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease; Data to Be Presented at 2025 ASH Congress

MaaT Pharma’s Pivotal Phase 3 ARES Trial Results for Xervyteg® (MaaT013) in Steroid- and Ruxolitinib-Refractory GI-aGvHD Selected for Oral Presentation at ASH 2025 MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem…








